Palovarotene | CHOP Research Institute
 

Palovarotene

1 - 3 of 3

FDA Approval, Mitochondrial Dysfunction, Pediatric Headaches

Published on
Aug 18, 2023
in Cornerstone Blog
In the News: FDA Approval, Mitochondrial Dysfunction
The FDA approved an oral drug, based on foundational research conducted at CHOP, to treat a rare, severe bone disease. More In The News.

CHOP Researchers Develop First Drug Treatment Approved for Severe Bone Disease

Published on
Jan 31, 2022
in Cornerstone Blog
CHOP Researchers Develop First Drug Treatment for FOP
Identified by CHOP researchers, palovarotene is the first drug approved (in Canada) for fibrodysplasia ossificans progressiva, a severe bone disease.

Vision Loss, New Division Chiefs, Allergies and Anxiety, SARS-CoV-2 Surveillance

Published on
Jul 23, 2021
in Cornerstone Blog
In The News
This week’s In the News features new study on measuring vision changes in patients with neurofibromatosis type 1, and other research highlights.
1 - 3 of 3